CCRM, OmniaBio, and Avectas Partner to Advance Cell Therapy Manufacturing
CCRM and its subsidiary OmniaBio have partnered with Avectas to evaluate an automated cell therapy manufacturing platform aimed at improving scalability and efficiency across a global network of advanced therapy hubs.